Category:
Other Excipients
CAS NO:
/
Standard:
In-house Standards,

"1, Treatment and prevention of osteoporosis in postmenopausal women; 2, Treatment for ostealgia caused by metastatic bone cancer; 3, Treatment for the hypercalcemia caused by malignant neoplasm with or without metastatic bone cancers." "Highlights: 1, Decrease 30%~50% of the ratio and of skeletal related event (SRE), defer the occurrence time; 2, the 3rd generation of diphosphonate, more excellent penetrability makes it to be one of the most active diphosphonate; 3, Over 500,000 patients have been treated in more than 50 countries (Boniva® by Roche). 4, Time to market: 2012 5,Originator: Boniva® by Roche Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part. "